Crossmark

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

Crossref DOI link: https://doi.org/10.1016/j.htct.2020.10.439

Published Print: 2020-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Maiolino, A.

Moreau, P.

Dimopoulos, M.

Mikhael, J.

Yong, K.

Capra, M.

Facon, T.

Hajek, R.

Spicka, I.

Risse, M.

Asset, G.

Macé, S.

Martin, T.
License Information

Text and Data Mining valid from 2020-11-01

Version of Record valid from 2020-10-13
More Information

This article is maintained by: Elsevier

Article Title: ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2020.10.439

Content Type: simple-article

Copyright: Copyright © 2020 Published by Elsevier Editora Ltda.

Document is current

Any future updates will be listed below